Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Meyerhardt JA, et al. Among authors: shi q. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. JAMA. 2021. PMID: 33821899 Free PMC article. Clinical Trial.
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. de Gramont A, et al. Among authors: shi q. J Clin Oncol. 2010 Jan 20;28(3):460-5. doi: 10.1200/JCO.2009.23.1407. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008641 Free PMC article.
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Among authors: shi q. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Chibaudel B, et al. Among authors: shi q. J Clin Oncol. 2011 Nov 1;29(31):4199-204. doi: 10.1200/JCO.2011.35.5867. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969501
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Franko J, et al. Among authors: shi q. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162570 Free PMC article. Clinical Trial.
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont A, Sargent D. Hubbard J, et al. Among authors: shi q. J Clin Oncol. 2012 Jul 1;30(19):2334-9. doi: 10.1200/JCO.2011.41.1975. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614981 Free PMC article.
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group. Cheung WY, et al. Among authors: shi q. Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27. Clin Colorectal Cancer. 2013. PMID: 23810482 Free PMC article. Clinical Trial.
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.
Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Shi Q, et al. J Clin Oncol. 2013 Oct 10;31(29):3656-63. doi: 10.1200/JCO.2013.49.4344. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980089 Free PMC article.
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology. Yoon HH, et al. Among authors: shi q. Clin Cancer Res. 2014 Jun 1;20(11):3033-43. doi: 10.1158/1078-0432.CCR-13-3140. Epub 2014 Mar 31. Clin Cancer Res. 2014. PMID: 24687927 Free PMC article. Clinical Trial.
7,900 results